Company research
Adverum Biotechnologies, Inc.
CIK 1501756Updated Sep 26, 2026
Name history
Adverum Biotechnologies, Inc. · through Dec 19, 2025Avalanche Biotechnologies, Inc. · through May 10, 2016
Filing activity
Latest filing
50 filings on record · 15-12G, EFFECT, 4, S-8 POS, POS AM, 8-K.
About the company
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
Recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 250,546,000Source | 173,010,000Source | 308,372,000Source | 439,727,000Source |
| Property, Plant and Equipment, NetUSD | 13,766,000Source | 14,764,000Source | 34,927,000Source | 33,060,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 149,608,000Source | 75,000,000Source | 68,431,000Source | 34,195,000Source |
| Assets, CurrentUSD | 199,130,000Source | 102,773,000Source | 190,595,000Source | 317,145,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,802,000Source | 6,247,000Source | 5,006,000Source | 6,248,000Source |
| Operating Lease, Right-of-Use AssetUSD | 34,478,000Source | 52,266,000Source | 78,934,000Source | 86,000,000Source |
| Other Assets, NoncurrentUSD | 1,196,000Source | 1,231,000Source | 1,413,000Source | 250,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 86,865,000Source | 89,541,000Source | 126,854,000Source | 123,542,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,000Source | 10,000Source | 10,000Source | 10,000Source |
| Retained Earnings (Accumulated Deficit)USD | -963,171,000Source | -919,777,000Source | -802,612,000Source | -648,076,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -533,000Source | -473,000Source | -1,531,000Source | -714,000Source |
| Stockholders' Equity Attributable to ParentUSD | 163,681,000Source | 83,469,000Source | 181,518,000Source | 316,185,000Source |
| Additional Paid in Capital, Common StockUSD | 1,127,383,000Source | 1,003,709,000Source | 985,651,000Source | 964,965,000Source |
| Liabilities and EquityUSD | 250,546,000Source | 173,010,000Source | 308,372,000Source | 439,727,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 16,578,000Source | 24,914,000Source | 32,246,000Source | 21,320,000Source |
| Operating Lease, Liability, CurrentUSD | 5,521,000Source | 10,409,000Source | 13,241,000Source | 1,886,000Source |
| Accounts Payable, CurrentUSD | 1,897,000Source | 1,921,000Source | 2,238,000Source | 1,387,000Source |
| Operating Lease, Liability, NoncurrentUSD | 70,287,000Source | 64,627,000Source | 93,561,000Source | 101,108,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 1,047,000Source | 1,114,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 96,500,000Source | 185,600,000Source | 305,200,000Source |
| Short-term InvestmentsUSD | 43,720,000Source | 21,526,000Source | 117,158,000Source | 270,993,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 14,350,000Source | 17,569,000Source | 20,079,000Source | 25,194,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -262,000Source | -369,000Source | 845,000Source | -1,612,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -92,462,000Source | -90,902,000Source | -108,091,000Source | -107,831,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -41,889,000Source | 96,875,000Source | 141,720,000Source | 78,709,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 388,000Source | 808,000Source | 11,816,000Source | 15,123,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 120,003,000Source | 69,000Source | 607,000Source | 2,397,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -14,348,000Source | 6,042,000Source | 34,236,000Source | -26,725,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 62,628,000Source | 76,976,000Source | 70,934,000Source | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | — | 0Source |
| Share-based Payment Arrangement, ExpenseUSD | 14,350,000Source | 17,569,000Source | 20,079,000Source | 25,194,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 125,700,000Source | 96,500,000Source | 185,600,000Source | 305,200,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -2,000Source | -50,000Source | -122,000Source | — |
| General and Administrative ExpenseUSD | 63,118,000Source | 49,915,000Source | 57,858,000Source | 64,441,000Source |
| Income Tax Expense (Benefit)USD | 0Source | -1,078,000Source | 74,000Source | 0Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 105,000Source | 1,057,000Source | -788,000Source | -428,000Source |
| Net Income (Loss) Attributable to ParentUSD | -130,927,000Source | -117,165,000Source | -154,536,000Source | -145,540,000Source |
| Nonoperating Income (Expense)USD | — | 5,748,000Source | 2,673,000Source | 582,000Source |
| Operating ExpensesUSD | 140,159,000Source | 127,591,000Source | 157,135,000Source | 153,622,000Source |
| Operating Lease, ExpenseUSD | — | — | 17,200,000Source | 12,800,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | 800,000Source |
| Other Nonoperating Income (Expense)USD | 8,232,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 1,685,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 60,400,000Source | 134,401,000Source | 257,899,000Source | 492,356,000Source |
| Proceeds from Stock Options ExercisedUSD | 146,000Source | 1,000Source | 3,000Source | 51,000Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | 1,600,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 1,000,000Source | 3,600,000Source | 0Source | 7,500,000Source |
| Operating Income (Loss)USD | -139,159,000Source | -123,991,000Source | -157,135,000Source | -146,122,000Source |
| Other Nonoperating Income (Expense)USD | 8,232,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -130,927,000Source | -118,243,000Source | -154,462,000Source | -145,540,000Source |
| Income Tax Expense (Benefit)USD | 0Source | -1,078,000Source | 74,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -130,927,000Source | -117,165,000Source | -154,536,000Source | -145,540,000Source |
| Earnings Per Share, BasicUSD per share | -6.62Source | -1.16Source | -1.56Source | -1.48Source |
| Earnings Per Share, DilutedUSD per share | -6.62Source | -1.16Source | -1.56Source | -1.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 19,782,000Source | 100,824,000Source | 99,251,000Source | 98,039,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 19,782,000Source | 100,824,000Source | 99,251,000Source | 98,039,000Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | -1,078,000Source | 74,000Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 3,653,000Source | 5,644,000Source | 6,528,000Source | 4,645,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 63,118,000Source | 49,915,000Source | 57,858,000Source | 64,441,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -130,768,000Source | -118,089,000Source | -154,002,000Source | -145,375,000Source |
| Nonoperating Income (Expense)USD | — | 5,748,000Source | 2,673,000Source | 582,000Source |
| Operating ExpensesUSD | 140,159,000Source | 127,591,000Source | 157,135,000Source | 153,622,000Source |
| Operating Lease, ExpenseUSD | — | — | 17,200,000Source | 12,800,000Source |
| Research and Development ExpenseUSD | 77,041,000Source | 77,676,000Source | 99,277,000Source | 89,181,000Source |
Filing attachments
d66011dex991.htm · 8-K · 2025-12-04
EX-99.1 2 d66011dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FLORetina • December 2025 Ixo-vec Gene Therapy for nAMD: Clinical Progress from the LUNA Phase 2 Trial Charles C. Wykoff, M.D., Ph. D. Director of Research, Retina Consultants of Texas Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital Disclosures: C= Consultant | R= Research Support | SO= Stock Options 4DMT (C, R), AbbVie (C, R), Adverum (C, R), AGTC (C), Alcon (C), Alexion (R), Alimera (C, R), Alke…
Read attachment ↗d70157dex991.htm · 8-K · 2025-10-24
EX-99.1 4 d70157dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 October 24, 2025 For Release: Immediately Refer to: Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media) Jason Awe, PhD; jawe@adverum.com; (Adverum) Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) Lilly to Acquire Adverum Biotechnologies Adverum’s lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with …
Read attachment ↗d937976dex991.htm · 8-K · 2025-09-22
EX-99.1 2 d937976dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration - Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026) - ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., September 22, 2025 - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneerin…
Read attachment ↗